Cancer Research Technology
Log in Register
Menu

Anti-LRAT [M34-P1F10]

Invented by Ayham Alnabulsi from Vertebrate Antibodies Limited
Invented at Vertebrate Antibodies Limited

Info

Catalogue Number 151869
Applications ELISA IHC IF WB
Antigen/Gene or Protein Targets Lecithin Retinol Acyltransferase (LRAT)
Reactivity Human
Relevance LRAT is significantly overexpressed in colorectal cancer and significantly associated with prognosis.
Host Mouse
Immunogen Peptide Sequence - RDQRSVLASA (amino acids 190 -199)
Positive Control ELISA- Peptide immunogenWestern Blot- Overexpression lysate Immunofluorescence- Hela Cells IHC- Human colon carcinoma
Subclass IgG1
Recommended Growing Conditions Dulbecco’s media containing 20% Fetal Bovine serum (DH20) prepared as follows (for final volume of 300ml: 237ml DMEM + 60 ml Fetal Bovine Serum plus 3ml L-Glutamine + 3ml of Penicillin -Streptomycin.
Strain Balb/c
Research Area Cell Signaling & Signal Transduction, Metabolism, Neurobiology

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Brown et al. 2014. PLoS One. 9(3):e90776. PMID: 24608339.

The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer.

Europe PMC ID: 24608339


Add a reference

References: 2 entries

Brown et al. 2014. PLoS One. 9(3):e90776. PMID: 24608339.

The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer.


Add a reference